The U.S. Food and Drug Administration concluded 2024 with 50 new drug approvals, marking a year of significant advancements in healthcare. Notable approvals include the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH), a prevalent and potentially fatal liver disease, and the first two treatments for Niemann-Pick disease type C, a rare genetic disorder. The FDA also greenlit innovative therapies for schizophrenia, hemophilia A or B, and pulmonary arterial hypertension.
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox.The U.S. Food and Drug Administration wrapped up 2024 with 50 new drug approvals , clearing a wave of long-awaited treatments.of new treatments not previously approved or marketed in the U.S. The total drugs cleared dipped slightly from 55 in 2023, but there were several firsts and other notable medications that the agency gave a green light last year.
Notably, many of the FDA approvals were for products from a mix of little known public and private companies, such as Allecra Therapeutics,Pharma. It signals that smaller biotech companies are more willing to bring their products to market on their own as opposed to partnering or getting acquired by a large pharmaceutical company.list last year, offers at-risk pricing models to self-insured employers to help their workers quickly access care and navigate benefits.
Transcarent will acquire Accolade for $7.03 per share in cash, which represents a premium of roughly 110% over its closing stock price on Tuesday, Transcarent said. The deal is expected to close next quarter, though it's still subject to shareholder and regulatory approvals. Evercore served as the financial adviser to Transcarent for the deal. Morgan Stanley advised Accolade.
FDA Drug Approvals Healthcare Liver Disease Genetic Disorders Schizophrenia Hemophilia Pulmonary Arterial Hypertension
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves 50 New Drugs in 2024, Marking Firsts for Several ConditionsThe U.S. Food and Drug Administration (FDA) concluded 2024 with 50 new drug approvals, ushering in a wave of groundbreaking treatments for various diseases. Among the notable approvals were the first-ever medications for metabolic dysfunction-associated steatohepatitis (MASH) and Niemann-Pick disease type C.
Read more »
FDA Approves Record Number of New Drugs in 2024The U.S. Food and Drug Administration (FDA) concluded 2024 with 50 new drug approvals, marking a significant year for medical advancements. The approvals included groundbreaking treatments for previously incurable diseases, such as metabolic dysfunction-associated steatohepatitis (MASH) and Niemann-Pick disease type C.
Read more »
FDA Approves Wave of New Treatments in 2024The U.S. Food and Drug Administration (FDA) concluded 2024 with 50 new drug approvals, including groundbreaking treatments for various diseases.
Read more »
FDA Approves 50 New Drugs in 2024, Marking Several FirstsThe US Food and Drug Administration (FDA) concluded 2024 with 50 new drug approvals, including groundbreaking treatments for conditions like metabolic dysfunction-associated steatohepatitis (MASH), Niemann-Pick disease type C, and schizophrenia.
Read more »
iPad Mini (2024) vs iPad Air (2024): Which One is Right for You?Apple's 2024 iPad lineup includes a refreshed iPad mini and a new iPad Air with two screen sizes. This comparison helps you decide between these two popular models.
Read more »
2024 Lookback: ‘Mufasa’ Meltdown Caps Unpredictable 2024 Box OfficeRevisiting 2024 box office predictions highlights missed expectations for “Mufasa,” “Joker,” “Inside Out 2,” “Deadpool” and more
Read more »